Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity [2]

Leukemia

Volumn 18, Issue 1, 2004, Pages 165-166

  Mailander V ^a   Scheibenbogen, C ^a   Thiel, E ^a   Letsch, A ^a   Blau, I W ^a   Keilholz, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; KEYHOLE LIMPET HEMOCYANIN; MELANOMA VACCINE; MITOXANTRONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; CANCER IMMUNIZATION; CANCER REGRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; ERYTHEMA; FATIGUE; HUMAN; IMMUNOGENICITY; LETTER; LUNG ASPERGILLOSIS; MINIMAL RESIDUAL DISEASE; NEPHROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT CANCER; SIDE EFFECT; SKIN INDURATION; THROMBOCYTE COUNT;

EID: 0742324477     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403186     Document Type: Letter

References (10)

1. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003; 17: 1301-1312.
2. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060-1067.
3. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-2976.
4. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51: 99-107.
5. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000; 164: 1873-1880.
6. Scheibenbogen C, Schadendorf D, Bechrakis N, Nagorsen D, Hofmann U, Servetopoulou F et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 2003; 104: 188-194.
7. Siehl J, Thiel E, Heufelder K, Snarsk E, Schwartz S, Mailander V et al. Regulation of Wilms' tumor gene 1(wt1) expression by the paired box genes PAX2 and PAX8 and by the hematopoietic transcription factor GATA-1 in human acute myeloid leukemias. Br J Hematol 2003; 123: 235-242.
8. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115-2121.
9. Menssen HD, Renkl HJ, Entezami M, Thiel E. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997; 89: 3486-3487.
10. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132-2137.